Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 17, 2025 07:00 ET | Source: AVACTA GROUP PLC

Faridoxorubicin (AVA6000) Phase 1b cohort demonstrates clinically meaningful tumor shrinkage in patients with salivary gland cancers

Avacta announced compelling new data in patients with salivary gland cancer enrolled in the ongoing Phase 1b trial of faridoxorubicin (AVA6000)